Patents by Inventor William Charles Ripka
William Charles Ripka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6951878Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP?, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.Type: GrantFiled: May 28, 2002Date of Patent: October 4, 2005Assignee: Novo Nordisk A/SInventors: Niels Peter Hundahl Møller, Henrik Sune Andersen, Lars Fogh Iversen, Ole Hvilsted Olsen, Sven Branner, Daniel Dale Holsworth, Farid Bakir, Luke Milburn Judge, Frank Urban Axe, Todd Kevin Jones, William Charles Ripka, Yu Ge, Roy Teruyuki Uyeda
-
Publication number: 20030069267Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like.Type: ApplicationFiled: May 28, 2002Publication date: April 10, 2003Inventors: Niels Peter Hundahl Moller, Henrik Sune Andersen, Lars Fogh Iversen, Ole Hvilsted Olsen, Sven Branner, Daniel Dale Holsworth, Farid Bakir, Luke Milburn Judge, Frank Urban Axe, Todd Kevin Jones, William Charles Ripka, Yu Ge, Roy Teruyuki Uyeda
-
Patent number: 6410586Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B. CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.Type: GrantFiled: March 16, 2001Date of Patent: June 25, 2002Assignees: Novo Nordisk A/S, Ontogen CorporationInventors: Niels Peter Hundahl Møller, Henrik Sune Andersen, Lars Fogh Iversen, Ole Hvilsted Olsen, Sven Branner, Daniel Dale Holsworth, Farid Bakir, Luke Milburn Judge, Frank Urban Axe, Todd Kevin Jones, William Charles Ripka, Yu Ge, Roy Teruyuki Uyeda
-
Patent number: 6342504Abstract: The present invention discloses peptide aldehydes which are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis.Type: GrantFiled: December 21, 1999Date of Patent: January 29, 2002Assignee: Corvas International, Inc.Inventors: Terence Kevin Brunck, Susan Y. Tamura, Joseph Edward Semple, Robert John Ardecky, Yu Ge, William Charles Ripka
-
Patent number: 6262044Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.Type: GrantFiled: March 11, 1999Date of Patent: July 17, 2001Assignees: Novo Nordisk A/S, Ontogen CorporationInventors: Niels Peter Hundahl Møller, Henrik Sune Andersen, Lars Fogh Iversen, Ole Hvilsted Olsen, Sven Branner, Daniel Dale Holsworth, Farid Bakir, Luke Milburn Judge, Frank Urban Axe, Todd Kevin Jones, William Charles Ripka, Yu Ge, Roy Teruyuki Uyeda
-
Patent number: 6034215Abstract: The present invention discloses peptide aldehydes which are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis.Type: GrantFiled: October 14, 1997Date of Patent: March 7, 2000Assignee: Corvas International, Inc.Inventors: Joseph Edward Semple, Robert John Ardecky, Ruth Foelsche Nutt, William Charles Ripka, David C. Rowley, Marguerita S. L. Lim-Wilby, Terence Kevin Brunck
-
Patent number: 6011158Abstract: The present invention discloses peptide aldehydes which are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis.Type: GrantFiled: June 7, 1996Date of Patent: January 4, 2000Assignee: Corvas International, Inc.Inventors: Susan Yoshiko Tamura, Joseph Edward Semple, William Charles Ripka, Robert John Ardecky, Yu Ge, Stephen H. Carpenter, Terence K. Brunck, Marguerita S. L. Lim-Wilby, Ruth F. Nutt, Matthew M. Abelman
-
Patent number: 6008351Abstract: The present invention discloses peptide aldehydes which are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis.Type: GrantFiled: December 18, 1995Date of Patent: December 28, 1999Assignee: Corvas International, Inc.Inventors: Susan Yoshiko Tamura, Joseph Edward Semple, William Charles Ripka, Robert John Ardecky, Yu Ge, Stephen H. Carpenter, Terence K. Brunck, Marguerita S. L. Lim-Wilby, Ruth F. Nutt, Matthew M. Abelman
-
Patent number: 5883107Abstract: The present invention provides peptide aldehydes having an azetidinyl, prolyl or pipecolyl group as part of the peptide backbone and an arginine mimic group such as an amidinopiperidine or amidinophenyl tail. These compounds are potent and specific inhibitors of thrombin. Their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis are also described.Type: GrantFiled: June 7, 1995Date of Patent: March 16, 1999Assignee: Corvas International, Inc.Inventors: Odile Esther Levy, Susan Yoshiko Tamura, Ruth Foelsche Nutt, William Charles Ripka
-
Patent number: 5883077Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The novel compounds include peptide aldehyde analogues having substantial potency and specificity as inhibitors of mammalian factor Xa are further disclosed. The compounds are thought useful as inhibitors of factor xa in vitro or as a therapeutic agent for the prevention and treatment of conditions characterized by abnormal thrombosis in mammals. Intermediates useful for the preparation of the novel compounds are also disclosed.Type: GrantFiled: December 15, 1993Date of Patent: March 16, 1999Assignee: Corvas International, Inc.Inventors: Terence Kevin Brunck, Thomas Roy Webb, William Charles Ripka
-
Patent number: 5807980Abstract: Compounds derived from BPTI which inhibit factor VIIa-TF complex with an inhibition constant of less than 500 nM, their pharmaceutical compositions, and methods of use. Also disclosed are isolated nucleic acid segments encoding for the compounds, vectors comprising the nucleic acid segment and promoter, transformed host cells, and a method for preparing the compounds using transformed host cells.Type: GrantFiled: July 1, 1993Date of Patent: September 15, 1998Assignee: Corvas International, Inc.Inventors: Ignace Lasters, Marc De Maeyer, William Charles Ripka
-
Patent number: 5747449Abstract: A compound derived from BPTI which inhibits Factor Xa with an inhibition constant less than 50 nM.Type: GrantFiled: July 1, 1993Date of Patent: May 5, 1998Assignee: Corvas International, Inc.Inventors: Ignace Lasters, Marc De Maeyer, William Charles Ripka
-
Patent number: 5739112Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The novel compounds include peptide aldehyde analogues having substantial potency and specificity as inhibitors of mammalian factor Xa are further disclosed. The compounds are thought useful as inhibitors of factor Xa in vitro or as a therapeutic agent for the prevention and treatment of conditions: characterized by abnormal thrombosis in mammals. Intermediates useful for the preparation of the novel compounds are also disclosed.Type: GrantFiled: June 5, 1995Date of Patent: April 14, 1998Assignee: Corvas International, Inc.Inventors: Terence Kevin Brunck, Thomas Roy Webb, William Charles Ripka
-
Patent number: 5731413Abstract: This invention provides solution-phase and solid-phase methods for the synthesis of peptidyl argininals and to ?novel! reagents useful therein.Type: GrantFiled: June 7, 1995Date of Patent: March 24, 1998Assignee: Corvas International, Inc.Inventors: Thomas Roy Webb, John Eugene Reiner, Susan Yoshiko Tamura, William Charles Ripka, Raymond Dagnino, Jr., Ruth Foelsche Nutt
-
Patent number: 5703208Abstract: The present invention discloses peptide aldehydes which are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis.Type: GrantFiled: June 7, 1995Date of Patent: December 30, 1997Assignee: Corvas International, Inc.Inventors: Joseph Edward Semple, Robert John Ardecky, Ruth Foelsche Nutt, William Charles Ripka, David C. Rowley, Marguerita S. L. Lim-Wilby, Terence Kevin Brunck
-
Patent number: 5658930Abstract: The present invention discloses peptide aldehydes which are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis.Type: GrantFiled: June 7, 1995Date of Patent: August 19, 1997Assignee: Corvas International, Inc.Inventors: Susan Yoshiko Tamura, Joseph Edward Semple, William Charles Ripka, Robert John Ardecky, Yu Ge, Stephen H. Carpenter, Terence K. Brunck
-
Patent number: 5656645Abstract: The present invention discloses heterocyclic aromatic peptide aldehydes which have an oxopyrimidine or oxopyridine group and an argininal tail which are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis.Type: GrantFiled: June 7, 1995Date of Patent: August 12, 1997Assignee: Corvas International, Inc.Inventors: Susan Yoshiko Tamura, Joseph Edward Semple, William Charles Ripka, Robert John Ardecky, Yu Ge, Stephen H. Carpenter, Terence K. Brunck
-
Patent number: 4077954Abstract: N-(p-methylphenethyl)-4a-aryl-trans-decahydroisoquinolines useful as analgesics.Type: GrantFiled: December 13, 1976Date of Patent: March 7, 1978Assignee: E. I. Du Pont de Nemours and CompanyInventor: William Charles Ripka
-
Patent number: 4042707Abstract: Certain 3.alpha.-arylhydroisoindoles are useful as analgesics and/or narcotic antagonists. Exemplary is N-cyclopropylmethyl-3.alpha.-(m-methoxyphenyl)-5,6-dimethyl-2,3,3.alpha.,4 ,7,7.alpha.-trans-hexahydroisoindole.Type: GrantFiled: February 19, 1976Date of Patent: August 16, 1977Assignee: E. I. Du Pont de Nemours and CompanyInventor: William Charles Ripka